A Remedy Worse than the Malady
From early in May 2020, doctors and hospitals began using remdesivir on hospitalized patients who tested positive for COVID in PCR tests. By November 9, 2021, the publication date of this book, CDC’s website lists only two drugs approved for treating COVID-19, remdesivir and the corticosteroid dexamethasone.75,76,77 Doctors often use the two drugs in conjunction. Assessing remdesivir’s impact on hospitalized COVID-19 patients is difficult, in part, because—like COVID-19—remdesivir causes extreme toxicity to lungs and kidneys,78 and mimics several of the other lethal symptoms of COVID, including multi-organ failure.79 Many doctors believe our country’s record COVID-19 fatalities are at least in part due to widespread use of remdesivir in 2020. “We had the most deaths worldwide,” says Dr. Ryan Cole. “It’s a haunting question: How many of these Americans were remdesivir casualties?”
For several months, we were the only country treating people with a drug proven to be lethal. That year, 2020, we had almost double the number of deaths per month compared to most other countries. Brazil, one of the first nations to widely use remdesivir, had the second highest death toll.80,81
In May of 2020, New York doctors repeatedly marveled at the tendency for COVID-19 to cause kidney failure, something that no other respiratory virus does. Doctors began seeing acute kidney failure on day three, four, and five after admission.82 Hospitals short on ventilators also ran out of dialysis machines. Physician and laboratory CEO Dr. Ryan Cole is one of many doctors who believe that many of those cases were attributable to remdesivir. “COVID-19 can affect the kidneys,” he says. “We know this because we can recover the spike protein from urine. But it’s dubious that the sheer magnitude of acute renal failure we saw among hospitalized COVID patients can all be attributed solely to the coronavirus infection.”
Dr. Cole told me that in the animal studies, one-fourth of the animals died from kidney failure. He explains that kidney collapse can lead to fluid accumulations in the lungs and everywhere and results in multi organ failure and sepsis—all of which are also sequelae of COVID. “Remdesivir shouldn’t be on the market,” he added.
Dr. Fauci’s 2019 Ebola study proved that remdesivir, by day three, four, and five, caused acute kidney failure in upwards of 31 percent of patients. In less than five days of remdesivir treatment, 8 percent of all people died or experienced life-threatening multiple organ failure or kidney failure so severe they had to be taken off the drug. “So it may not be a coincidence that roughly the same number of hospitalized COVID patients—8–10x were dying in the first week,” says Cole.
Dr. McCullough gives us a stark and clear summary: “Remdesivir has two problems. First, it doesn’t work. Second, it is toxic and it kills people.”
V: FINAL SOLUTION: VACCINES OR BUST
“The only means to fight a plague is honesty.”
—Albert Camus, The Plague (1947)
During the spring of 2020, Dr. Fauci and Bill Gates carpet-bombed the airwaves, bearishly predicting that a “miraculous vaccine” would stop COVID transmission, prevent illness, end the pandemic, and release humanity from house arrest. Even vaccinology’s most stalwart tub thumpers—true believers like Dr. Peter Hotez and Dr. Paul Offit—regarded those forecasts as far-fetched and foolhardy.1,2 After all, for decades, two perilous and seemingly insurmountable impediments had thwarted every attempt to craft a coronavirus vaccine.
Leaky Vaccines
The first obstacle was the coronavirus’s tendency to rapidly mutate, producing vaccine-resistant variants. Vaccine developers like Hotez and Offit doubted that, after decades of futile efforts, researchers could suddenly develop a COVID vaccine that would provide “sterilizing immunity,” meaning that it would completely obliterate viral colonies in vaccinated individuals and prevent transmission and mutation.
As if to confirm such fears, in May of that year, Britain’s top vaccinologist, Andrew Pollard, admitted that the Oxford University’s government-funded and patriotically ballyhooed AstraZeneca vaccine had failed to achieve sterilizing immunity in monkeys; the inoculated macaques, even when asymptomatic, continued to support high viral loads in their nasal pharynxes.3 Then in August, Dr. Fauci primped up the dismaying news of similar failures by all the competing candidates with a kind of celebratory bravado. Instead of declaring defeat and retreating to the drawing board, Dr. Fauci cheerfully announced that none of the first-generation COVID vaccines was likely to prevent transmission.4 That news should have cratered the entire project. Leading virologists, including Nobel Laureate Luc Montagnier, pointed out that a non-sterilizing, or “leaky,” vaccine could not arrest transmission and would therefore fail to stop the pandemic.5 Even worse, vaccinated individuals, he warned, would become asymptomatic carriers and “mutant factories” blasting out vaccine-resistant versions of the disease that were likely to lengthen and intensify rather than abbreviate the pandemic.
But Tony Fauci and his partner, Bill Gates, seemed to have a strategy for neutralizing the variant threat. The two men had put billions of taxpayer and tax-deducted dollars into developing an mRNA platform for vaccines that, in theory, would allow them to quickly produce new “boosters” to combat each new “escape variant.” This scheme was Big Pharma’s holy grail. Vaccines are one of the rare commercial products that multiply profits by failing. Each new booster doubles the revenues from the initial jab. Since NIAID co-owned the mRNA patent,6 the agency stood to make billions from its coronavirus gambit by producing successive boosters for every new variant; the more, the better! The good news for Pharma was that all of humanity would be permanently dependent on biannual or even triannual booster shots. Dr. Peter McCullough warned that mass vaccination with a leaky vaccine during a pandemic “would put the world on a never-ending booster treadmill.”7 That kind of talk had Pharma popping champagne corks. In October 2021, Pfizer announced that it was projecting an astonishing $26 billion in revenues from its COVID boosters.8